Shishida Masayuki, Toyota Kazuhiro, Ikeda Masahiro, Karakuchi Nozomi, Inoue Masashi, Saito Yasufumi, Takahashi Tadateru
Department of Surgery, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Case Rep Oncol. 2020 Jun 16;13(2):689-695. doi: 10.1159/000507781. eCollection 2020 May-Aug.
Gastric cancer incidence is high in several countries, and management of advanced gastric cancer remains a challenge. Chemotherapy for unresectable gastric cancers is still evolving, and achieving a complete cure is difficult. Although a clinical complete response to chemotherapy has been reported in patients with unresectable gastric cancer, the chemotherapy duration for these patients is unclear. Here, we report the case of a 71-year-old man who presented with abdominal discomfort. Upper endoscopy revealed advanced gastric cancer on the upper gastric body. Histopathological examination revealed a poorly differentiated adenocarcinoma. Computed tomography revealed regional lymph node and multiple bilobar hepatic metastases. Radical surgery was not possible; therefore, palliative resection of the primary lesion was planned for symptomatic improvement. Tegafur, 5-chloro-2,4-dihydro-pyrimidine, and potassium oxonate were administered prior to surgery, and proximal gastrectomy was performed. Tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate administration was reinitiated after surgery. A clinical complete response was achieved in the 8th postoperative month, with no hepatic metastases noted on radio imaging. Computed tomography performed in the 1st postoperative year revealed ascites; however, the cytological examination findings were negative. The initial chemotherapy was discontinued, and paclitaxel administration was commenced. Computed tomography performed annually thereafter demonstrated no recurrence, and paclitaxel was discontinued in the 9th postoperative year. The patient remained recurrence free at 12 years postoperatively. For elderly patients like the one presented here, it may be necessary to consider ceasing chemotherapy; however, because it is possible for a complete clinical response over the long term, it should be continued if the patient is well.
胃癌在一些国家的发病率较高,晚期胃癌的治疗仍然是一项挑战。不可切除胃癌的化疗仍在不断发展,实现完全治愈很困难。虽然已有报道不可切除胃癌患者对化疗有临床完全缓解,但这些患者的化疗持续时间尚不清楚。在此,我们报告一例71岁男性患者,其因腹部不适就诊。上消化道内镜检查显示胃体上部存在进展期胃癌。组织病理学检查显示为低分化腺癌。计算机断层扫描显示有区域淋巴结及双侧多发肝转移。无法进行根治性手术;因此,计划行姑息性切除原发灶以改善症状。术前给予替加氟、5-氯-2,4-二氢嘧啶和奥替拉西钾,随后进行近端胃切除术。术后重新开始给予替加氟、5-氯-2,4-二氢嘧啶和奥替拉西钾。术后第8个月实现了临床完全缓解,影像学检查未发现肝转移。术后第1年进行的计算机断层扫描显示有腹水;然而,细胞学检查结果为阴性。停用初始化疗,开始给予紫杉醇。此后每年进行的计算机断层扫描均未显示复发,术后第9年停用紫杉醇。患者术后12年无复发。对于像本文所介绍的这类老年患者,可能有必要考虑停止化疗;然而,由于有可能实现长期的临床完全缓解,如果患者情况良好,化疗应继续进行。